CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 1.27B |
| Revenue (ttm) | 68.55M |
| Net Income (ttm) | -149.15M |
| Shares Out | 511.25M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,360,000 |
| Average Volume | 4,635,550 |
| Open | 2.550 |
| Previous Close | 2.490 |
| Day's Range | 2.500 - 2.640 |
| 52-Week Range | 0.123 - 3.500 |
| Beta | 0.01 |
| RSI | 45.97 |
| Earnings Date | Mar 30, 2026 |
About CANbridge Pharmaceuticals
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinu... [Read more]
Financial Performance
In 2024, CANbridge Pharmaceuticals's revenue was 85.10 million, a decrease of -17.27% compared to the previous year's 102.87 million. Losses were -442.62 million, 16.8% more than in 2023.
Financial numbers in CNY Financial StatementsNews
China's Push To Expand Access To Costly Therapies And A Partnership Deal Boost Rare Drugs Maker - But Is It Enough?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies Key Takeaways： A drug distribu...